Bridgepoint Plans to Sell Drugs Maker Aenova for About $510 Million

Private equity group Bridgepoint has hired Morgan Stanley to sell Aenova, hoping to get more than 400 million euros ($510 million) for the German vitamins and generic prescription drugs maker, two people familiar with the situation said. Aenova is set to join a growing list of medium-sized German businesses going up for sale as private equity groups trawl their portfolios looking for strong disposal candidates. An auction for Aenova is planned for the autumn, the people said, and is expected to attract rival vitamin makers such as German chemicals group BASF and Dutch supplements maker DSM, as well as private equity firms.